Compliance and persistence with osteoporosis therapies

被引：28
|
作者：
Silverman S.L. [1 ]
Gold D.T. [1 ]
机构：
[1] University of California, Los Angeles/Cedars-Sinai, Beverly Hills, CA 90211
来源：
Current Rheumatology Reports | 2008年 / 10卷 / 2期
关键词：
Osteoporosis; Bisphosphonates; Alendronate; Zoledronic Acid; Risedronate;
D O I：
10.1007/s11926-008-0021-x
中图分类号：
学科分类号：
摘要：
The US Food and Drug Administration has approved a diverse group of effective osteoporosis therapies. However, these therapies obviously only work when patients with osteoporosis take them. Data from retrospective observational databases have shown poor compliance and persistence with all osteoporosis drugs, particularly oral bisphosphonate therapy. Patients on weekly therapies are more compliant and persistent than those on daily dosing. Data have also shown decreased fracture risk, decreased health care utilization, and lower costs in compliant and persistent patients. Copyright © 2008 by Current Medicine Group LLC.
引用
收藏
页码：118 / 122
页数：4
相关论文
共 50 条
  • [21] Parkinson's disease drug therapies: medication compliance and persistence
    Tarrants, M.
    Denarie, M.
    Karabas, T.
    Castelli-Haley, J.
    Millard, J.
    Zhang, D.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S135 - S135
  • [22] A Retrospective Longitudinal Database Study of Persistence and Compliance with Treatment of Osteoporosis in Hungary
    Péter Lakatos
    István Takács
    István Marton
    Emese Tóth
    Cina Zoltan
    Zsolt Lang
    Emi Psachoulia
    Michele Intorcia
    Calcified Tissue International, 2016, 98 : 215 - 225
  • [23] A new look at osteoporosis outcomes: The influence of treatment, compliance, persistence, and adherence
    Badamgarav, Enkhe
    Fitzpatrick, Lorraine A.
    MAYO CLINIC PROCEEDINGS, 2006, 81 (08) : 1009 - 1012
  • [24] Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis
    Cramer, JA
    Amonkar, MM
    Hebborn, A
    Altman, R
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (09) : 1453 - 1460
  • [25] A Retrospective Longitudinal Database Study of Persistence and Compliance with Treatment of Osteoporosis in Hungary
    Lakatos, Peter
    Takacs, Istvan
    Marton, Istvan
    Toth, Emese
    Zoltan, Cina
    Lang, Zsolt
    Psachoulia, Emi
    Intorcia, Michele
    CALCIFIED TISSUE INTERNATIONAL, 2016, 98 (03) : 215 - 225
  • [26] ADHERENCE, COMPLIANCE, AND PERSISTENCE WITH LIPID-LOWERING THERAPIES: A SYSTEMATIC REVIEW
    Xu, Y.
    Worden, C.
    VALUE IN HEALTH, 2016, 19 (03) : A50 - A50
  • [27] Parkinson's Disease Drug Therapies: Medication Compliance and Persistence Update
    Tarrants, Marcy L.
    Millard, Jennifer
    Zhang, Dongmu
    Rudolph, Sarah
    Foote, Adam
    Castelli-Haley, Jane
    NEUROLOGY, 2011, 76 (09) : A402 - A402
  • [28] PERSISTENCE & COMPLIANCE TO TREATMENT FOR OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN IN HUNGARY: A RETROSPECTIVE COHORT STUDY
    Lakatos, Peter
    Toth, Emese
    Kovacs, Eszter
    Lang, Zsolt
    Psachoulia, Emi
    Intorcia, Michele
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 : S196 - S196
  • [29] The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment
    Marco Invernizzi
    C. Cisari
    S. Carda
    Aging Clinical and Experimental Research, 2015, 27 : 107 - 113
  • [30] PERSISTENCE & COMPLIANCE TO TREATMENT FOR OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN IN HUNGARY: A RETROSPECTIVE COHORT STUDY
    Lakatos, P.
    Toth, E.
    Cina, Z.
    Lang, Z.
    Psachoulia, E.
    Intorcia, M.
    VALUE IN HEALTH, 2013, 16 (07) : A567 - A568
12345